Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Xếp hạng trong cổ phiếu #5435
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the... AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Giá cổ phiếu
$169.98
Đồng bộ lần cuối: 2026-09-25
Vốn hóa thị trường
$2.64B
Thay đổi (1 ngày)
0.69%
Thay đổi (1 năm)
16.30%
Quốc gia
GB
Giao dịch AstraZeneca PLC (AZN)

Danh mục

Doanh thu của AstraZeneca PLC (AZN)
Doanh thu vào Jun 2026 TTM: $61.37B
Theo các báo cáo tài chính gần đây của AstraZeneca PLC, doanh thu hiện tại của công ty (TTM) là $61.37B. Trong năm 2024, công ty đạt doanh thu $54.07B tăng so với doanh thu năm 2023, là $45.81B. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của AstraZeneca PLC từ 2000 đến 2026
Doanh thu vào cuối mỗi năm
Năm Doanh thu Thay đổi
2026 (TTM) $61.37B 4.47%
2025 $58.74B 8.63%
2024 $54.07B 18.03%
2023 $45.81B 3.29%
2022 $44.35B 18.53%
2021 $37.42B 40.58%
2020 $26.62B 9.16%
2019 $24.38B 10.38%
2018 $22.09B -1.67%
2017 $22.47B -2.33%
2016 $23.00B -6.90%
2015 $24.71B -6.93%
2014 $26.55B 2.87%
2013 $25.81B -7.75%
2012 $27.97B -16.72%
2011 $33.59B 0.97%
2010 $33.27B 1.42%
2009 $32.80B 3.81%
2008 $31.60B 6.91%
2007 $29.56B 11.65%
2006 $26.48B 10.54%
2005 $23.95B 11.78%
2004 $21.43B 13.67%
2003 $18.85B 5.65%
2002 $17.84B 8.26%
2001 $16.48B -9.03%
2000 $18.12B 0.00%
Doanh thu của các công ty hoặc đối thủ tương tự
Công ty Doanh thu Chênh lệch doanh thu Quốc gia
$79.67B 29.82%
US
$97.93B 59.58%
US
$64.39B 4.92%
US
$77.52B 26.32%
CH
$66.40B 8.20%
US